FLINT, Mich. – March 17, 2015 – As part of a limited panel, the nation’s largest independent specialty pharmacy will offer PARI’s cystic fibrosis treatment, a 28-day supply of Tobramycin Inhalation Solution together with a PARI LC PLUS® nebulizer handset.

Diplomat Pharmacy, Inc. (NYSE: DPLO) announced its selection today to the limited-distribution panel for PARI’s KITABIS™ PAK, recently approved by the U.S. Food and Drug Administration for patients with cystic fibrosis.

Cystic fibrosis is a life-threatening disease that affects nearly 30,000 American patients. The condition involves a genetic mutation that produces abnormally thick mucus in the lungs, which can often result in respiratory infection. KITABIS™ PAK is used to treat patients age 6 and older with cystic fibrosis who have a bacterial infection called Pseudomonas aeruginosa.

KITABIS™ PAK is an FDA-approved drug-and-device combination for cystic fibrosis, and the first to use nebulized tobramycin, an inhalable antibiotic. A prescription for KITABIS™ PAK includes the medication and the nebulizer handset, PARI LC PLUS®.

“This unique offering can simplify the process for prescribers and patients facing cystic fibrosis,” said Gary Kadlec, president of Diplomat. “Now, physicians can write a single prescription and be sure their patients are receiving their treatments with the nebulizer handset used during the pivotal clinical trials. We’re excited to be able to offer it, for improved access, adherence and efficacy.”

KITABIS™ PAK is distributed by PARI Respiratory Equipment Inc. Full prescribing information is available at http://kitabis.com/wp-content/uploads/pdfs/Kitabis-Pak-Full-Prescribing-Information.pdf

 

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements relating to Diplomat’s distribution of the drug(s) set forth above (and any implied financial impact). The forward-looking statements contained in this press release are based on management’s good-faith belief and reasonable judgment based on current information, and these statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. These risks include the number of patients prescribed such drug(s) currently and in the future, patient’s adherence to such drug(s), the number of distributors on panel and our relative distribution share, the timing of drug sales, the cost of such drug(s) and reimbursement rates by payors, drug competition, and the factors set forth in “Risk Factors” in Diplomat’s Annual Report on Form 10-K for the year ended December 31, 2014 and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable law, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.

About Diplomat

Diplomat (NYSE: DPLO) serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients, and the rest falls into place.” Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information visit www.diplomat.is.

###

CONTACT:

Gary Rice, RPH, MS, MBA, CSP,
Vice President, Clinical Services
810.768.9863 | grice@diplomat.is

Kali Lucas, Public Relations Specialist
810.768.9580 | press@diplomat.is

Twitter